Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00289614 · ClinicalTrials.gov registry record · Phase 4
Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)
A Phase 4 study, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 4
- Development phase
- 350
- Enrollment target
NCT00289614: Completed Phase 4 study, sponsored by Bracco Diagnostics.
NCT00289614 is a Phase 4 study that has completed, run by Bracco Diagnostics. The registered enrollment target is 350 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00289614, a Phase 4 study, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 350 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue (iopamidol) or Visipaque in diabetic patients with moderate to severe chronic renal impairment undergoing clinically indicated contrast enhanced multidetector computed tomography (MDCT). Serum creatinine will be measured before and up to 48-72 hours post dose.
Interventions
- DRUG Iopamidol 370 mgI/dL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
What the finished NCT00289614 record still lists
NCT00289614 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which Iopamidol 370 mgI/dL is the first listed.
NCT00289614 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00289614 about?
NCT00289614 is a clinical study titled "Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)". The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue (iopamidol) or Visipaque in diabetic patients with moderate to severe chronic renal impairment undergoing clinically indicated contrast enhanced multidetector computed...
What is the current status of trial NCT00289614?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 350 participants. The study started on 2006-01. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00289614?
The interventions under investigation include: Iopamidol 370 mgI/dL (DRUG).
Who is sponsoring clinical trial NCT00289614?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00289614's enrollment target sits among peer trials
350 231st of 2000 higher than 1,761 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia